R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
HebaBiz Biotech is pleased to announce that in November 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) of China has approved the application...
November 16, 2021
by prnasia
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development
MIMETAS announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
July 7, 2021
by b3cnewswire
CaroGen, BioCentriq Enter Clinical Manufacturing Pact
BioCentriq to provide clinical manufacturing to support Phase 1 clinical trials of CaroGen's lead immunotherapy candidate, CARG-201.
June 23, 2021
by contractpharma
Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients
Enanta Pharmaceuticals, Inc. today announced positive data from the first two dose cohorts of its Phase 1b study of EDP-514 in viremic chronic HBV patients who were not being treated with a nucleoside reverse transcriptase inhibitor (NUC).
June 23, 2021
by firstwordpharma
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology
Innovent Biologics, Inc. today announced that data from the ORIENT-32 study have been published in The Lancet Oncology.
June 21, 2021
by prnasia
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® ...
February 4, 2021
by prnasia
Vaccitech Doses First Patient in HBV002 for Chronic HBV
Vaccitech announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with CHB infection.
February 4, 2021
by americanpharmaceuticalreview
Antios Completes Phase 1b Clinical Trial of ATI-2173 for Chronic Hepatitis B Virus Infection
Antios Therapeutics has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection.
January 26, 2021
by americanpharmaceuticalreview
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
January 15, 2021
by pharmatimes
Assembly Biosciences to Wind-Down Microbiome Program
Assembly Biosciences will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic hepatitis B virus (HBV).
December 30, 2020
by americanpharmaceuticalreview
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ...
December 4, 2020
by prnasia
Extension Study of Vebicorvir for Chronic HBV Does Not Achieve Meaningful SVR Rates
Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response (SVR) could be ...
November 16, 2020
by americanpharmaceuticalreview